心脏代谢健康对局部高危前列腺癌术前激素治疗疗效的影响
本研究对104例接受3-6个月术前ADT+/-ARPI的局部高危前列腺癌患者进行事后分析,评估肥胖和循环脂质代谢物与病理缓解及PSA进展的关系。结果显示,术后较低的内脏和皮下脂肪与病理缓解相关,而脂肪增加与PSA进展风险升高相关,脂质代谢物变化在应答者与非应答者间存在差异。
要点
- 术后较低内脏脂肪(VATi p=0.002)和皮下脂肪(SATi p=0.004)与病理缓解相关。
- 术后脂肪每增加10单位,VATi HR 1.09(p=0.04),SATi HR 1.14(p=0.03)与PSA进展相关。
- 脂质代谢物变化与病理应答相关,支持心脏代谢健康与前列腺癌的阶段依赖性关联。
核心结论
- 术后较高脂肪量和脂质代谢物途径的个体内变化与术前激素治疗后较差结局相关。
研究设计与样本
- 对104例局部高危前列腺癌患者的事后分析,患者来自三项试验,接受3-6个月术前ADT+/-ARPI。
- 基线及根治性前列腺切除术时(EOT n=56)通过L3 CT量化身体组成。
- 基线(n=60)和配对基线/EOT(n=59)样本通过UPLC-MS分析血浆脂质代谢物。
主要发现
- 中位年龄63岁,76.9%为Gleason分级组4-5,43.7%为临床T3-4疾病。
- 根治性前列腺切除术时较低内脏脂肪(VATi p=0.002)和皮下脂肪(SATi p=0.004)与病理缓解相关。
- 根治性前列腺切除术时脂肪增加与PSA进展相关(每10单位增加:VATi HR 1.09,p=0.04;SATi HR 1.14,p=0.03)。
- 配对分析(n=59)中,病理应答者显示二酰甘油和含多不饱和脂肪酸酰基链的甘油三酯(PUFA-TAGs)下降(p<0.05)及神经酰胺种类升高。
- 非应答者显示PUFA-TAGs和甘油磷脂增加(p<0.05),以及溶血磷脂酰胆碱种类、长链酰基肉碱和胆固醇降低。
关键数值与推荐
- 病理缓解定义为根治性前列腺切除术时≤T2N0。
- PSA无进展生存期定义为从根治性前列腺切除术至PSA≥0.2 ng/mL或开始放疗的时间。
临床怎么用
- 评估局部高危前列腺癌患者术前激素治疗时,可考虑身体组成和脂质代谢状态对疗效的潜在影响。
局限性
- 事后分析,样本量有限,部分分析样本量较小(如EOT身体组成n=56,脂质配对分析n=59)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Altered lipid metabolism, adiposity, and androgens have been linked to cardiac disease and prostate cancer. Adiposity increases risk of recurrence for prostate cancer and may enhance response to androgen receptor pathway inhibition (ARPI). We evaluated whether adiposity and circulating lipid metabolites are associated with response to pre-operative ADT + /- ARPI in localized high-risk prostate cancer (HRPCa). METHODS: We performed a post hoc analysis of 104 men with localized HRPCa treated with 3-6 months of preoperative ADT + /- ARPI across three trials. Body composition was quantified from L3 CT imaging at baseline and at radical prostatectomy (RP; end-of-treatment [EOT] n = 56). Plasma lipid metabolites were profiled by UPLC-MS at baseline (n = 60) and in paired baseline/EOT samples (n = 59). Pathologic response was defined as ≤ T2N0 at RP. PSA progression-free survival (PFS) was defined as time from RP to PSA ≥ 0.2 ng/mL or initiation of radiotherapy. RESULTS: Median age was 63 years, 76.9% had Gleason grade group 4-5, and 43.7% had clinical T3-4 disease. At RP, lower visceral (VATi, p = 0.002) and subcutaneous adiposity (SATi, p = 0.004) were associated with pathologic response. Increasing adiposity at RP was associated with PSA progression (per 10-unit increase: VATi HR 1.09, p = 0.04; SATi HR 1.14, p = 0.03). In paired analyses (n = 59), pathologic responders demonstrated decreases (p < 0.05) in diacylglycerols and polyunsaturated fatty acyl chain-containing triacylglycerols (PUFA-TAGs) and elevations in ceramide species. Non-responders exhibited increases (p < 0.05) in PUFA-TAGs and glycerophospholipids with reductions in lysophosphatidylcholine species, long-chain acylcarnitine, and cholesterol. CONCLUSIONS: Higher post-treatment adiposity and intrapatient changes in lipid metabolite pathways were associated with inferior outcomes after pre-operative hormone therapy, supporting a stage-dependent link between cardiometabolic health and prostate cancer that warrants further elucidation.
引用
- Boshkos M, Moura Nascimento Santos MJ, Tidwell RS, et al. Cardiometabolic health's influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer. Prostate Cancer Prostatic Dis. 2026. PMID: 42881232. doi:10.1038/s41391-026-01163-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。